Intriguingly, only dual targeting of YAP and treatment with MEK inhibitors could blunt expression of a conserved set of genes active in different cancer types; the enhancers of these genes were shown to be jointly regulated by YAP/TAZ and AP-1 factors, with MEK inhibitors causing specific loss of AP-1 association to chromatin [18]. The gene discussed is FOS; the disease is cancer.